Welcome to our dedicated page for JUPITER NEUROSCIENCES SEC filings (Ticker: JUNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a biotech filing packed with pharmacokinetic charts and clinical risk factors is hard enough; add Jupiter Neurosciences� focus on neuro-inflammation chemistry and the pages multiply quickly. If you have ever searched for “Jupiter Neurosciences SEC filings explained simply�, you already know the challenge. Our platform removes the guesswork and delivers a Jupiter Neurosciences annual report 10-K simplified—complete with plain-English explanations of JOTROL research milestones, cash runway metrics, and FDA-related risk disclosures.
Stock Titan’s AI models scan every line the instant it hits EDGAR, whether it is a Jupiter Neurosciences quarterly earnings report 10-Q filing, an 8-K disclosing interim trial data, or a Jupiter Neurosciences Form 4 insider transactions real-time alert. Need to monitor “Jupiter Neurosciences executive stock transactions Form 4� before the market reacts or understand a sudden “Jupiter Neurosciences 8-K material events explained�? Our AI highlights the who, what, and why, then links directly to the original document for audit-ready transparency.
Investors use these insights to track R&D expense trends, anticipate dilution, and benchmark progress against peer pipelines. Want an at-a-glance view of insider confidence? The dedicated dashboard surfaces every “Jupiter Neurosciences insider trading Form 4 transactions� with context. Curious about governance? Drill into the “Jupiter Neurosciences proxy statement executive compensation� section to see how option grants align with trial milestones. From “Jupiter Neurosciences earnings report filing analysis� to understanding Jupiter Neurosciences SEC documents with AI, the information you need is distilled, summarized, and ready for immediate action—no PhD in medicinal chemistry required.
Jupiter Neurosciences (JUNS) Form 4 filing: President, Chief Business Officer and Director Alison D. Silva reported three open-market purchases on 01 July 2025 totaling 750 common shares at an average price of roughly $1.03 per share. Following the transactions, Silva directly owns 112,777 shares of JUNS common stock. No derivative security activity was disclosed.
The transactions are coded “P,� indicating routine open-market buys and not part of a Rule 10b5-1 trading plan. While the dollar value is modest (� $770), insider buying is generally interpreted as a vote of confidence in the company’s prospects. However, the size of the purchase is immaterial to overall share count and does not meaningfully affect ownership structure.
FAQ
What is the current stock price of JUPITER NEUROSCIENCES (JUNS)?
What is the market cap of JUPITER NEUROSCIENCES (JUNS)?
